Cytosorbents (CTSO) EPS (Basic) Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -47.75% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 43.85% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.90% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 14.55% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -25.84% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 42.13% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 15.81% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 72.17% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 13.85% |
| 10 | Cytosorbents | 19.47 Mn | 15.06 Mn | 7.05 Mn | -326.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -326.15% |
| Mar 31, 2026 | -235.70% |
| Dec 31, 2025 | 36.46% |
| Sep 30, 2025 | 0.63% |
| Jun 30, 2025 | 139.33% |
| Mar 31, 2025 | 79.22% |
| Dec 31, 2024 | -6.39% |
| Sep 30, 2024 | 75.46% |
| Jun 30, 2024 | 43.44% |
| Mar 31, 2024 | 30.15% |
| Dec 31, 2023 | -643.14% |
| Sep 30, 2023 | 25.95% |
| Jun 30, 2023 | 44.03% |
| Mar 31, 2023 | 18.65% |
| Dec 31, 2022 | 91.81% |
| Sep 30, 2022 | -89.53% |
| Jun 30, 2022 | -131.29% |
| Mar 31, 2022 | -113.92% |
| Dec 31, 2021 | -1,129.48% |
| Sep 30, 2021 | -36.23% |